Heidi Roschitzki-Voser

Head Trial Activities

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Heidi Roschitzki-Voser is the Head of Trial Activities at the ETOP IBCSG Partners Foundation in Switzerland. Her research focuses on oncology, specifically the treatment and prognosis of lung cancer and malignant pleural mesothelioma. She has contributed significantly to studies evaluating immunotherapy, targeted treatments, and the impact of patient factors on treatment efficacy. Her recent work includes pivotal trials examining the effectiveness of various combination therapies in advanced non-small cell lung cancer (NSCLC) and mesothelioma.

Articles (9)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

SARAH DANSON

University of Sheffield

UNITED KINGDOM

View details

Kenneth O'Byrne

Queensland University of Technology

AUSTRALIA

View details

Reyes Bernabé

Universidad de Sevilla

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Heidi Roschitzki-Voser

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

Collaborators (3)

SARAH DANSON

Kenneth O'Byrne

Reyes Bernabé

Make your next move.